146 related articles for article (PubMed ID: 11593892)
1. [Ablative therapy for immune hyperthyroidism in patients with ophthalmopathy].
Lind P
Acta Med Austriaca; 2001; 28(4):105-7. PubMed ID: 11593892
[TBL] [Abstract][Full Text] [Related]
2. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
3. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
4. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?
Weetman AP; Harrison BJ
J Endocrinol Invest; 1998; 21(7):472-5. PubMed ID: 9766265
[TBL] [Abstract][Full Text] [Related]
5. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
Marcocci C; Bruno-Bossio G; Manetti L; Tanda ML; Miccoli P; Iacconi P; Bartolomei MP; Nardi M; Pinchera A; Bartalena L
Clin Endocrinol (Oxf); 1999 Oct; 51(4):503-8. PubMed ID: 10583319
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
7. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
Tallstedt L; Lundell G; Blomgren H; Bring J
Eur J Endocrinol; 1994 May; 130(5):494-7. PubMed ID: 8180678
[TBL] [Abstract][Full Text] [Related]
8. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?
Marcocci C; Bartalena L; Pinchera A
J Endocrinol Invest; 1998; 21(7):468-71. PubMed ID: 9766264
[No Abstract] [Full Text] [Related]
9. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
10. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
[TBL] [Abstract][Full Text] [Related]
12. Endocrine ophthalmopathy and radioiodine therapy.
Karlsson FA
Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.
Tallstedt L; Lundell G
Thyroid; 1997 Apr; 7(2):241-5. PubMed ID: 9133694
[TBL] [Abstract][Full Text] [Related]
14. Chronology of Graves' ophthalmopathy in an incidence cohort.
Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
[TBL] [Abstract][Full Text] [Related]
15. (131)I and thyroid-associated ophthalmopathy.
Rasmussen AK; Nygaard B; Feldt-Rasmussen U
Eur J Endocrinol; 2000 Aug; 143(2):155-60. PubMed ID: 10913933
[TBL] [Abstract][Full Text] [Related]
16. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease.
Willemsen UF; Knesewitsch P; Kreisig T; Pickardt CR; Kirsch CM
Eur J Nucl Med; 1993 Nov; 20(11):1051-5. PubMed ID: 8287872
[TBL] [Abstract][Full Text] [Related]
17. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
18. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.
Barth A; Probst P; Bürgi H
J Endocrinol Invest; 1991 Mar; 14(3):209-12. PubMed ID: 2071823
[TBL] [Abstract][Full Text] [Related]
19. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM).
Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y
Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111
[TBL] [Abstract][Full Text] [Related]
20. [Paradoxical effect of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy].
Dunkelmann S; Rudolph F; Prillwitz A; Groth P; Schümichen C
Nuklearmedizin; 1998 Jan; 37(1):23-9. PubMed ID: 9467166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
